Show simple item record

dc.contributor.authorChilds, Michelle
dc.date.accessioned2010-10-29T14:19:04Z
dc.date.available2010-10-29T14:19:04Z
dc.date.issued2010-07-01
dc.identifier.citationOpen AIDS J. 2010 Jan 19;4:33-6en
dc.identifier.issn1874-6136
dc.identifier.pmid20148090
dc.identifier.doi10.2174/1874613601004020033
dc.identifier.urihttp://hdl.handle.net/10144/114125
dc.description.abstractRecent WHO guidelines for antiretroviral therapy recommend switching to less toxic, but more expensive medicines for first-line and second-line ART, raising questions about the financial sustainability of many AIDS treatment programmes. At the same time, many key generic producing countries such as India now grant pharmaceutical product patents so competition between multiple manufacturers will not be able to play the role it has in bringing down the price of newer drugs.Overcoming these patent barriers will require a range of solutions, such as restricting patentability criteria, or compulsory licensing. One additional systematic solution is provided by the patent pool, a collective solution to the management of patent rights, initially presented by Médecins Sans Frontières to the French Foreign Ministry and subsequently the UNITAID Executive Board in 2006.A patent pool must not be implemented at any costs, but answer medical needs, be based on economic realities and meet the access needs of the developing world, including middle-income countries.
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817875/?tool=pubmeden
dc.rightsArchived with thanks to The Open AIDS Journalen
dc.subject.meshHIV/AIDSen
dc.subject.meshpatentsen
dc.titleTowards a Patent Pool for HIV Medicines: The Backgrounden
dc.typeArticleen
dc.contributor.departmentCampaign for Access to Essential Medicines, Médecins Sans Frontières, Geneva, Switzerlanden
dc.identifier.journalThe Open AIDS journalen
refterms.dateFOA2019-03-04T08:24:08Z
html.description.abstractRecent WHO guidelines for antiretroviral therapy recommend switching to less toxic, but more expensive medicines for first-line and second-line ART, raising questions about the financial sustainability of many AIDS treatment programmes. At the same time, many key generic producing countries such as India now grant pharmaceutical product patents so competition between multiple manufacturers will not be able to play the role it has in bringing down the price of newer drugs.Overcoming these patent barriers will require a range of solutions, such as restricting patentability criteria, or compulsory licensing. One additional systematic solution is provided by the patent pool, a collective solution to the management of patent rights, initially presented by Médecins Sans Frontières to the French Foreign Ministry and subsequently the UNITAID Executive Board in 2006.A patent pool must not be implemented at any costs, but answer medical needs, be based on economic realities and meet the access needs of the developing world, including middle-income countries.


Files in this item

Thumbnail
Name:
33TOAIDJ.pdf
Size:
346.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record